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CARDIOVASCULAR EFFECTS OF DILTIAZEM IN THE DOG
K. SKARVAN AND H.-J. PRIEBE
Despite improvements in the anaesthetic manage-
ment of patients with coronary artery disease, the
occurrence of myocardial ischaemia is still a
serious threat during the perioperative period.
Ischaemia is usually associated with tachycardia,
arterial hypertension, increased wall tension or
coronary vasoconstriction [1]. Consequently, the
ideal treatment should decrease arterial and
ventricular filling pressures, and heart rate, and
decrease coronary artery tone without having any
adverse effects on myocardial contractility and
conduction. Diltiazem is one of the recently-
introduced calcium entry blockers available for
i.v. use in man. In its oral form it is highly
effective in the management of angina pectoris [2].
When administered i.v. to conscious subjects, it is
a potent coronary and systemic vasodilator with-
out evidence of untoward effects on heart rate or
myocardial contractility [3, 4]. In addition, it
possesses antiarrhythmic properties [5, 6], and
protects the myocardium from ischaemic and
reperfusion injury [7, 8]. Thus it may be well
suited for the treatment of perioperative myo-
cardial ischaemia. However, the efficacy and
safety of diltiazem during anaesthesia remain to
be determined as hypotension, bradycardia and
abnormalities of conduction have been reported
after i.v. administration in anaesthetized man, and
anaesthetized animals [9, 10].
The aim of this study was to investigate the
effects of bolus injections and constant infusions
of diltiazem on the systemic, pulmonary and
coronary circulations, on global and regional left
(LV) and right ventricular (RV) function, and on
the ECG during neuroleptanaesthesia. Admini-
stration of nitroglycerin (TNG) before and after
the administration of diltiazem served to assess
the effects of anaesthesia and of diltiazem on
baroreceptor function.
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SUMMARY
The effects of two bolus injections (0.2 mg kg'1)
and two infusion rates (0.2 mg min'1 and
0.4 mg min'1) of diltiazem on global and regional
left (LV) and right ventricular (RV) performance
(ultrasonic dimension technique), on coronary
(electromagnetic flow meters) and systemic
haemodynamics. and on electrophysiology (PR.
QRS, QTC intervals) were studied in eight open-
chest dogs anaesthetized with droperidol and
fentanyl. The two bolus injections of diltiazem
resulted in plasma concentrations of 688 ± 115
and 650 ± 85 ng ml~' (means ± SE), respectively,
and caused substantial decreases in systemic
and coronary vascular resistances, and in aortic
pressure, and increases in LV segment shorten-
ing, stroke volume and aortic flow. Electro -
physiological variables were little affected. At
the low infusion rate (plasma concentration
140±23 ng ml'1) coronary and systemic vaso-
dilatation occurred, but global and regional RV
and LV performance were little affected. PR
interval increased by 15%. At the higher infusion
rate (plasma concentration 282±33 ng ml'1)
coronary and systemic vasodilatation were main-
tained. Aortic pressure decreased slightly.
Whereas LV end-diastolic and end-systolic
dimensions remained unchanged, they increased
in the RV. In addition, the PR interval increased
by 35%, and three animals developed atrio-
ventricular block type I. The data indicate that
diltiazem is a potent coronary and systemic
vasodilator with little effect on global RV and L V
performance. However, at a higher infusion rate
RV dimensions clearly tend to increase, and
conduction abnormalities develop.
METHODS
Instrumentation
Eight mongrel dogs of either sex weighing
between 27 and 33 kg received fentanyl
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0.04 mg kg"1 and a large dose of droperidol
(2 mg kg"1) i.m. 1 h before the induction of
anaesthesia. After this premedication the dogs
became heavily sedated, recumbent, and did not
resist the placement of a peripheral venous cannula.
Anaesthesia was induced with small incremental
doses of pentobarbitone i.v. up to a maxi-
mum total of 10 mg kg"1 and then maintained
with continuous infusions of pentobarbitone
1 mg kg"1 h"1 i.v., and fentanyl 20 ug kg"1 h"1 i.v.
Additional bolus doses of fentanyl 500 ug were
given i.v. whenever increases in heart rate and
arterial pressure, or movements, indicated a
decrease in the depth of anaesthesia. The trachea
was intubated and controlled ventilation (Harvard
constant-volume ventilator, Harvard Apparatus
Co., South Natick, MA) facilitated by a con-
tinuous infusion of pancuronium 0.04 mg kg"1 h"1
i.v. Tidal volume was set at 15 ml kg"1. Ven-
tilatory rates and inspired oxygen concentrations
were adjusted to maintain the arterial carbon
dioxide tension (PaCOa) between 4 and 5.3 kPa and
the arterial oxygen tension (PaOl) between 20 and
46.7 kPa. Positive end-expiratory pressure (2 cm
H2O) was applied to prevent major airway collapse
in the open-chest animals. Sodium bicarbonate
was administered if the calculated base deficit
exceeded 5 mmol litre"1. All dogs were in the
supine position and placed on a heating element
incorporated in the operating table. Body tem-
perature was monitored continuously by the
thermistor of a flow-directed thermodilution
catheter (Edwards Laboratory, Santa Ana, CA,
Model 93-132-5F) inserted through the right
jugular vein into the pulmonary artery. All
animals received 4-6 ml kg"1 h"1 of physiological
saline i.v.
Catheter-tip manometers (6F, Millar Instru-
ments Inc, Houston, TX) were advanced into the
ascending aorta just above the aortic valve, and
into the left and right ventricles. The catheter-tip
manometers were prewarmed in a water bath at
37 °C for several hours, and they were calibrated
simultaneously and immediately before insertion.
Calibration was performed by actuating a switch
incorporated in the connection cable that pro-
duced an electrical output corresponding to a
pressure of 100 mm Hg. Baseline stability of the
high-fidelity signals was verified repeatedly
during the experiment by superimposing the
manometer-derived pressures on those derived
either from the separate fluid-filled catheter in the
aortic arch, or from the fluid-filled lumina in-
corporated in the RV and LV catheter-tip mano-
meters using Statham transducers (P23 ID). The
chest was entered through a median sternotomy
and the heart was suspended in a pericardial
cradle. Precalibrated electromagnetic flow probes
(Stolzer Messtechnik, Waldkirch, West Germany)
of appropriate sizes (to ensure a snug fit) were
placed around the ascending aorta, the right
coronary artery (RCA) approximately 1-2 cm
distal to its origin, and the left anterior descending
coronary artery (LAD) distal to its first large
diagonal branch. The flow probes were connected
to flow meters with incorporated non-occlusive
zero (Hellige Co., Freiburg i. Br., West Germany).
Regional myocardial function
Regional myocardial performance was evalu-
ated by sonomicrometry [11, 12]. Pairs of piezo-
electric crystals (5 MHz, 1.5-2.0 mm diameter)
were inserted into the subendocardium of the
inflow (longitudinal direction) and outflow tract
(transverse direction) of the RV (RVIT and
RVOT). A third pair was inserted in an equatorial
plane into the subendocardium of the LV distal to
the first or second diagonal branch of the LAD.
Care was taken to place the crystals in the inflow
tract of the RV and those in the apical region of
the LV within the areas supplied by the RCA and
LAD, respectively. Myocardial segment lengths
(SL) between each pair of crystals were deter-
mined at end-diastole (SLed) and at the time
of maximal shortening during systole (SLsys).
From these values, percent segment shortening
during systole (ASL) was derived [ASL (%) =
(SLcd-SLsys)/SLed x 100]. End-diastole was de-
fined as the beginning of the sharp upslope in the
expanded LV and RV pressure tracings, and end-
systole by the dicrotic notch in the aortic pressure
signal as derived from the catheter-tip mano-
meters. Analysis of aortic flow and pressure
signals in several animals showed that zero aortic
flow and the dicrotic notch occurred within 40 ms
of each other. The ultrasonic signals were also
assessed visually for qualitative changes such as
akinesis, paradoxical systolic segment lengthening
or postsystolic segment shortening.
Haemodynamic measurements
A multichannel recorder (Hellige Co., Freiburg
i. Br., West Germany) was used for the continuous
recording of all signals. LV dP/dt was derived
from LV high-fidelity signals using operational
amplifiers connected to a differentiator (Hellige
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Co., Freiburg i. Br., West Germany). Right
(RVSW) and left ventricular stroke work (LVSW),
and stroke volume (SV) were derived from
standard formulae. Systemic (SVR), pulmonary
(PVR), and right (CVRR) and left anterior
descending (CVRLAD) coronary artery vascular
resistances were derived from the following
formulae:
SVR (dyn s cm"5)
MAoP (mm Hg) - RVEDP (mm Hg)
 OA
= ——
 : X80
AoF mm
PVR (dyn s cm"5)
_ PPA (mm Hg)-LVEDP (mm Hg) ^
 SQ
AoF (litre min"1)
CVRlt (kdyn s cm"5)
MAoP (mm Hg)-RVEDP (mm Hg)
CBFlt (ml min"1) x80
x80
CVRLAD (kdyn s cm"5)
_ AoP(l (mm Hg)-LVEDP (mm Hg)
~ CBFIAI) (ml min-1)
where MAoP = mean aortic pressure, RVEDP =
right ventricular end-diastolic pressure, AoF =
mean aortic flow, PPA = mean pulmonary artery
pressure, LVEDP = left ventricular end-diastolic
pressure, CBFR = mean right coronary artery
blood flow, AoPd = end-diastolic aortic pressure,
and CBF,
 AI) = mean left anterior descending
coronary artery blood flow. Heart rate (HR) was
derived from the R-R intervals of an extremity
ECG.
Electrocardiographic (ECG) measurements
Lead II of the ECG was recorded continuously
and analysed for evidence of arrhythmias and
conduction abnormalities. Five consecutive car-
diac cycles recorded at end-expiration at a chart
speed of 100 mm s"1 were used for the measure-
ments of the PR, QRS and QT intervals. QTC
intervals were calculated according to the formula:
QTC =
QT
v/RR
where RR = cycle length of ECG (s).
Experimental programme
After sternotomy, and approximately 2 h before
the start of the experiment, pentobarbitone was
discontinued. Any adjustments in ventilation,
acid-base status, depth of anaesthesia, and fluid
administration were made no later than 30 min
before the start of the definitive study.
Hydrophilized diltiazem hydrochloride dis-
solved in distilled water was freshly added to
0.9 % sodium chloride to yield concentrations of
1 mg ml"1 and 0.4 mg ml"1 for bolus injection and
continuous infusion, respectively. Commercially
available i.v. nitroglycerin (Trinitrosan, Merck)
5 mg ml"1 was diluted in 0.9 % sodium chloride to
obtain a concentration of 50 ng ml"1.
Following control readings a bolus dose of
TNG 5 ng kg"1 was administered. After the
return of all measured variables to control values
(C), a bolus dose of diltiazem 0.2 mg kg"1 was
administered. This was followed by a continuous
infusion (0.2 mg min"1) which was maintained for
30 min. Immediately after the measurements, a
further i.v. bolus of diltiazem 0.2 mg kg"1 was
given, and the infusion rate was doubled
to 0.4 mg min"1 and maintained at this rate
for 30 min. Finally, an additional bolus of
TNG 5 ug kg"1 was administered. Measurements
following the bolus injections of TNG and dil-
tiazem were made at the time of the lowest
AoP which occurred within 1 min of injection.
Measurements during the infusions were made
during steady-state conditions at the end of each
of the two 30-min infusion periods of diltiazem
(0.2 mg min"1 = Dl l n r; 0.4 mg min"1 = D2inr).
Arterial blood was sampled during C and at the
end of each diltiazem infusion period for deter-
minations of haematocrit (Hct) (Microcentrifuge
Compur, Munich, West Germany, Model
Ml 100), arterial blood-gas tensions and arterial
pH (Instrumentation Laboratory, Lexington,
MA, Model 613), and plasma concentrations of
diltiazem. Additional measurements of diltiazem
plasma concentrations were obtained following
the two bolus injections. Diltiazem was assayed by
electron-capture gas-liquid chromatography. As
internal standard the butyryl analogue of diltiazem
was used. This method has an overall sensitivity
of less than 5 ng/ml of plasma [13].
Statistical analysis
The data were analysed statistically by Fried-
man's statistic. If this indicated statistical signi-
ficance, the Wilcoxon signed-rank test was used to
isolate the significant difference between treat-
ments by making paired comparisons [14]. A
P value of < 0.05 was considered significant.
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TABLE I. Effects of diltiazem on systemic haemodynamics and left ventricular function (mean±SE).
C = control; D1M and D2M = first and second i.v. bolus injection of diltiazem 0.2 mg kg'1; Dlln, and
D2lnf= infusions of diltiazem 0.2 mg min~l and 0.4 mg min'1, respectively. LVSLrd = left ventricular (LV)
end-diastolic segment length; LVSLtyt = LV systolic segment length; ALVSL = LV systolic segment
shortening; LVEDP = LV end-diastolic pressure; MAoP = mean aortic pressure; HR = heart rate;
AoF = aortic flow; SV = stroke volume; LVSW = LV stroke work; SVR — systemic vascular resistance.
+P < 0.05 when compared with C; *P < 0.05 when compared with preceding value; §P < 0.05 when
D2lnf compared with Dlinl
Variable
LVSL^ (mm)
LVSLsys (mm)
ALVSL (%)
LVEDP (mm Hg)
MAoP (mm Hg)
LV dP/dtmax(mm Hg s"1)
HR (beat min-1)
AoF (litre mirr1)
SV (ml beat"1)
LVSW (g m)
SVR (dyn s cm-5)
C
9.2 ±0.4
6.3 + 0.3
31.2 + 2.7
5.9±0.4
94 + 3
2492 + 163
94 + 6
2.0 + 0.2
22 + 2
27±3
3649 + 177
9.1+0.4
5.8 + 0.4t
35.4 ±3.8+
5.7±0.4
75 + 4 |
2521 ±183
103 ±6t
2.5 + 0.2
24 ±2+
23 + 3f
2349+ 78t
Dl i n ,
9.2 + 0.2
6.1+0.3
33.1+2.7
5.8 + 0.4
92 + 4*
2531 + 172
97 + 6*
2.3 + 0.2
24±3
28 + 4*
3261+152+*
D2,,,,
9.4 + 0.3
5.8 + 0.3
38.7±3.5f*
5.9 + 0.6
75+4f*
2598 + 222
97+4
2.6 ±0.3+*
26 + 3+*
26 + 4
2294 ±127+*
D2InI
9.4 + 0.3
6.3 + 0.2
32.5 ±2.9
6.2 + 0.7
88 + 2+*
2492 ±185
94 + 6
2.3±0.3
25±3f
28 ±4
3127±292+'
TABLE II. Effects of diltiazem on pulmonary haemodynamics and right ventricular function (mean + SE).
RVITSLtd = right ventricular (RV) inflow tract (IT) end-diastolic segment length; RVISTL,y, = RVIT
systolic segment length; ARVITSL = RVIT systolic segment shortening; RVOTSLed = RV outflow tract(OT) end-diastolic segment length; RVOTSL,y, = RVOTsystolic segment length; 4RVOTSL = RVOT
systolic segment shortening; RVEDP = RV end-diastolic pressure; RVSP = RV systolic pressure;
PPA = mean pulmonary artery pressure; RVSW = RV stroke work; PVR = pulmonary vascular resistance.
(See table I for further abbreviations)
Variable Dl,, D2,,
RVITSLed (mm)
RVITSLsys (mm)
ARVITSL (%)
RVOTSLea (mm)
RVOTSLsy, (mm)
ARVOTSL (%)
RVEDP (mm Hg)
RVSP (mm Hg)
PPA (mm Hg)
RVSW (g m)
PVR (dyn s cm"6)
10.3±0.6
8.1 ±0.6
22.0 ±1.4
10.5 ±0.8
8.0 ±0.7
24.1 ±1.7
3.6±0.3
29±2
13+1
2.9±0.6
274 + 31
10.7+0.6+
8.3±0.6
22.9±2.0
10.9±1.0f
8.2 ±0.8
25.7±1.5
4.1 ±0.4
30±l
14±1
3.4±0.7t
275 + 25
10.4±0.6
8.2 + 0.6
21.6±1.9
10.9 + 1.0+
8.2 ±0.7
25.1 + 1.5
3.9±0.3
30 + 2
13±1
3.0±0.5
274 ±33
10.9 ±0.7+*
8.4 ±0.7+
23.3±1.9
11.3±1.0+*
8.4+0.8+
25.6±1.1
4.5 ±0.4+*
31±2
14±1
3.6±0.6+*
267 ±26
10.8±0.7+§
8.4 ±0.7+
22.7±1.7
11.3±0.9+
8.4±0.7+
25.7±1.6
3.9±0.3
29±2
14±1
3.5±0.6§
280 + 34
RESULTS
Effects of bolus injections of diltiazem on systemic
and pulmonary haemodynamics, and on RV and
LV function (tables I and II)
The two bolus injections of diltiazem resulted
in plasma concentrations of 688+ 115 (Dlbol) and
650 + 85 ng ml"1 (D2bol)> respectively. The first
bolus injection (D1,)O]) caused a decrease in MAoP
accompanied by increases in HR and AoF, and a
decrease in SVR and LVSW. LVEDP and LV
dP/drmax remained unchanged. LVSLsys de-
creased, and ALVSL increased. In contrast to the
response of the LV and the systemic circulation,
RVITed and RVOTed increased; ASL djd not
change. RV systolic pressure (RVSP), PAP and
RVSW tended to increase, and PVR remained
unchanged.
In contrast to DlbO|, the second bolus injection
(D2b0|) given at the end of the lower-dose infusion
had no effect on HR, despite a similar decrease in
MAoP. It caused additional increases in
RVITSLsys and RVOTSL5ys, and in RVEDP.
All other effects were comparable to Dlbo,.
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TABLE III . Effects of dihiazem on left and right coronary haemodynamics (mean + SE). CBFLAD =
mean left anterior descending coronary artery blood flow; CBFK = mean right coronary artery blood flow.
(See table I for further abbreviations)
Variable D l h Dl,, D2,,
CBF,
 AD (ml min ')
CBFK (ml min"1)
CVRIAI1 (kdynscnr5)
CVRK (kdyn s cm"5)
CBFLAD/HR Oil bear')
CBFH/HR (ul beat"1)
CBF,AD/AoF100(%)
CBFH/AoF100(%)
27 + 3
14±2
241 ±23
530 ±40
286 ±32
154± 16
1.32 + 0.13
0.72 ±0.06
43 + 7t
25±3t
115±17t
257±36|
412 + 53t
237 + 26+
1.74±0.21t
1.01±0.11+
32 + 4 |*
18±2+*
194±23f*
406±37f*
330 + 37f*
187±19f*
1.51 ±0.21
0.86±0.11+*
43 + 6f*
26±3+*
l l l±15t*
242 ±36+*
442 + 55+*
267 ±31+*
1.76±0.23+
1.07±0.13+*
36±5+*§
21±2+*§
171±24+*§
343 ±39+*
380±51+§
222±18+*§
1.69±0.27§
0.99 ±0.13+
There were no qualitative changes in sono-
micrometry signals—such as akinesis or para-
doxical systolic segment lengthening.
Effects of bolus injections of dihiazem on coronary
haemodynamics (table III)
Following Dlbol there were pronounced in-
creases in coronary blood flow (CBF), in CBF per
heart beat (CBF/HR) and in CBF expressed as a
fraction of AoF (CBF/AoF), and a decrease in
CVR. These responses were clearly blunted
during D2bol.
Effects of the infusion of dihiazem on systemic and
pulmonary haemodynamics, and on LV and RV
function (tables I and II)
The two infusion rates of diltiazem resulted in
plasma concentrations of 140 + 23 ng ml"1 (Dl,nf)
and 282 + 33 ng ml"1 (D2inr), respectively. Except
for a slight decrease in SVR, the low infusion rate
(Dllnr) had no significant effects on systemic
haemodynamics or LV function. At the higher
infusion rate (D2lnr) there was a small (7%)
decrease in MAoP, and increases (13 %) in SV and
AoF. However, when compared with each other
there were no differences between Dllnf and D2lnf.
Except for an isolated increase in RVOTSLed3
Dl ln t had no significant effect on RV function or
on the pulmonary circulation. At the higher
infusion rate (D2lnr), however, end-diastolic and
end-systolic dimensions of RVIT and RVOT,
and RVSW increased without changes in segment
shortening. PAP and PVR remained unchanged
throughout. As with the bolus doses, there were
no qualitative changes in the sonomicrometry
signals.
Effects of the infusion of diltiazem on left and
right coronary haemodynamics (table III)
During both infusion periods there were
marked increases in CBF, in the amount of
coronary blood flow per heart beat (CBF/HR)
and in the ratio of CBF and AoF (CBF/AoF),
accompanied by similar decreases in CVR.
Correlation between plasma concentrations of
diltiazem and haemodynamic effects
There were significant negative correlations
between the plasma concentrations of diltiazem
and changes in MAoP (r = -0 .62 , P < 0.01),
SVR (r = - 0 . 6 5 , P < 0.01), CVR,,An (r = - 0 . 5 8 ,
P < 0.01) and CVRR (r = - 0 . 3 8 , P < 0.05).
Effects of diltiazem on cardiac rhythm and
electrophysiological variables (table IV)
QRS and QTC intervals remained unchanged
throughout. During the infusions and following
the second bolus injection, the PR interval
increased. Three of the eight animals developed
second degree atrioventricular block type I
(Wenckebach) during the infusion of diltiazem at
the higher rate.
Effects of TNG (table V)
The two bolus injections of TNG administered
either before (TNG,) or after (TNG2) the second
diltiazem infusion resulted in similar decreases
(30%) in MAoP and similar increases (20-25%)
in HR.
Changes in pHa, PzOl, PaCOi, Hct and tempera-
ture were minimal throughout the experiment
(table VI).
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TABLE IV. Effects of diltiazem on electrocardiographic variables (mean±SE). (See table I for further
abbreviations)
Variable
PR(s)
QRS (s)
QTC (s)
C
0.14 + 0.01
0.08 + 0.01
0.33 + 0.01
0.13±0.01
0.07 + 0.01
0.34±0.01
0.16 + O.Olf*
0.07 ±0.01
0.32 + 0.01
0.15±0.01t
0.07 + 0.01
0.32 + 0.01
D2ln,
0.19±0.02f*
0.07 ±0.01
0.33 ±0.01
TABLE V. Effect of nitroglycerin-induced hypotension on heart
rate before and after diltiazem (mean±SE). TNGl,
TNG2 = nitroglycerin (TNG) 5-\ig kg'1 bolus administered
before (TNG,) and after (TNG2) diltiazem infusion (D2(nl).
* P < 0.05 when compared with the preceding value. (See
table I for further abbreviations)
Variable T N G , D2,, T N G ,
MAoP (mm Hg)
HR (beat mirr1)
96±3
91±7
68 ±4*
117 + 6*
88±2
94±9
63 ±3*
114 + 4*
TABLE VI. Effects of experimental procedure on general homeo-
slasis (mean + SE). (See table I for further abbreviations)
Variable D2 l
pHa
PaOi (kPa)
P*co, (kPa)
Hct (%)
Temp. (°C)
7.37±0.01
33.1 ±2
5.1 ±0.13
35 + 1
37.6 + 0.2
7.37±0.01
31.6±2.53
4.9±0.13t
37±lt
37.6 ±0.2
7.37±0.01
31.2+2.93*
4.8 + 0.13+
38±lt
37.6±0.2
DISCUSSION
The purpose of this study was to examine the
effects of i.v. administration of diltiazem on the
cardiovascular system during neuroleptanaes-
thesia.
Diltiazem i.v. at clinically relevant plasma
concentrations caused substantial systemic and
coronary vasodilatation, and it enhanced LV
pump function. At the same time, however,
diltiazem caused dose-dependent prolongation of
atrioventricular conduction. There were im-
portant differences between the effects of the bolus
injections and the infusions of diltiazem, and
differences between the effects on RV and LV
function and on the different circulations.
Critique of methods
The design of the study simulated the clinical
situation in which diltiazem is given to patients
undergoing open heart surgery. In addition, the
second bolus injection of diltiazem, given on top
of the lower rate infusion, approximated the
clinical situation in which those patients receiving
diltiazem before operation receive an additional
dose during the operative procedure.
Clinically relevant plasma concentrations of
diltiazem were achieved during both infusion
rates [15, 16]. The bolus injections resulted in
considerably higher values. The plasma concen-
trations after the second bolus injection were
lower than expected and statistically not different
from those found after the first bolus. At present
we have no explanation for this finding.
The cardiovascular effects of a calcium entry
blocker given during operation depend on the
interactions with the anaesthetic drugs used and
on the baseline conditions of the circulation. In
this study the anaesthesia was based on droperidol
given in a large dose i.m. before induction of
anaesthesia, and on fentanyl given as a continuous
infusion and supplemented with additional bolus
doses when required. While adverse interactions
have been described between diltiazem and in-
halation anaesthetic agents [10, 17, 18], the effects
of diltiazem during i.v. anaesthesia have not been
studied as yet. The baseline haemodynamic status
was characterized by a normal heart rate, a normal
arterial pressure and a slightly decreased aortic
flow. This haemodynamic pattern closely
resembles the clinical situation following sterno-
tomy and pericardiotomy [19]. The dis-
continuation of pentobarbitone 2 h before the
measurements should have minimized myocardial
depression [20], but, with regard to the long
elimination half-time of pentobarbitone, a poten-
tial for later interactions cannot be totally
excluded. In addition, negative inotropic influ-
ences may be more pronounced in the open-chest
than in the closed-chest animal [21]. Nevertheless,
the lower baseline aortic flow appears to be
primarily the result of the opening of the chest,
positive pressure ventilation, and reductions in
venous return and ventricular filling.
On the other hand, normal heart rates and
arterial pressures during the control period indi-
cate that there was no inappropriate sympatho-
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adrenergic stimulation. The responsiveness of the
autonomic nervous system, however, was well
maintained, as demonstrated by the baroreflex-
mediated tachycardia after nitroglycerin.
Effects of diltiazem on systemic and pulmonary
circulations
Diltiazem proved to be a potent systemic
vasodilator. This is in accordance with previous
studies [3, 22]. Except during the low-dose
infusion, the reductions in SVR were accom-
panied by a decrease in AoP. In contrast, diltiazem
did not alter PVR and PAP. Similar results have
been reported previously [9, 23-25].
Coronary circulation
Diltiazem proved to be a potent coronary
vasodilator. A direct vasodilatory effect appeared
to dominate, since CBF and CBF/HR increased
in the presence of decreases in coronary perfusion
pressure and evidence of reduced myocardial
oxygen demand.
The changes in the coronary circulation were
more pronounced than the respective changes in
the systemic circulation (fig. 1). This would
indicate that diltiazem is an even more powerful
10 o.
PVR
SVR
>CVR
D2 i n ,
FIG. 1. Changes in pulmonary (PVR), systemic (SVR), and
left anterior descending coronary artery vascular resistances
(CVR) from control (C) to the first infusion rate of diltiazem
(Dl,nf) and from Dl ln, to the second infusion rate of diltiazem(D2,nr). Mean values during control have all been standard-
ized to an initial value of 10. There was a significant differ-
ence (P < 0.05) between the changes of PVR and CVR. SVR
tended (P < 0.1) to respond less than CVR and more than
PVR to the infusion of diltiazem.
coronary, than systemic, vasodilator. This has
previously been suggested [26]. The effects of
diltiazem on the coronary circulation appear to
vary with the baseline anaesthetic. In contrast to
the results of this study, CVR did not change
in dogs anaesthetized by isoflurane or enflurane
[17, 18].
Diltiazem and ventricular performance
Diltiazem had no adverse effects on global right
(RVSP, RVSW) or left (AoF, SV, LVSW)
ventricular performance. This is in agreement
with results of previous studies which have shown
that, in therapeutic doses, diltiazem has little
effect on inotropy in intact animals or in awake
man [3, 27]. However, when looking at our data in
greater detail, differences in the response to
diltiazem between RV and LV, and in the effects
of bolus injections and infusions become apparent.
Segment shortening and stroke volume increased
following the bolus injections, but no such effects
were noted during the low-dose infusion, and
were less prominent during the high-dose in-
fusion. There are several possible explanations for
this difference. First, the decreases in SVR were
more pronounced following the bolus injections.
At constant preload, a decrease in SVR tends to
increase the volume ejected from and returning to
the LV [28]. This can be viewed as an upward
shift of the LV function curve [29] and could
explain the improved LV pump function.
Second, because of the greater decrease in
MAoP following the bolus injections, there might
have been a more pronounced baroreflex-
mediated increase in sympathetic outflow, result-
ing in increased contractility. However, the
findings of an unchanged LV dP/dr, and an un-
changed HR, following the second bolus injection
do not support such a mechanism.
Third, during the infusions of diltiazem some
myocardial depression might have outweighed the
beneficial effects of a decrease in afterload on LV
function. A direct negative inotropic effect of
diltiazem has been demonstrated in vitro [27].
The fact that no such effect was noted following
the bolus injections, despite considerably higher
plasma concentrations, can best be explained by a
greater barorefiex-mediated increase in sym-
pathetic tone or the counterbalancing effect of a
greater decrease in LV afterload.
The LV end-diastolic dimension and pressure
remained unchanged throughout. The systemic
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FIG. 2. Plot of end-diastolic segment lengths (SL^,) v. stroke volume (SV). Mean values during control
(C) have all been standardized to an initial value of 10. The arrows indicate the directional changes from
control to the first infusion rate of diltiazem (Dllnf), and from Dl ln r to the second infusion rate of
diltiazem (D2lnf). Note the differences in slopes of the SV-SLed relationship between left and right
ventricle. There is a trend (P < 0.1) to right- and downward shift of the SV-SLcd relationship in the
RVIT and RVOT when compared with LV.
vasodilatation, however, usually shifts the dia-
stolic pressure—volume curve of the LV down-
wards [30]. Correspondingly, in the presence of
an unchanged LV end-distolic dimension (and
volume), the LVEDP should have decreased.
Several factors may be responsible for the
absence of any changes in LVEDP. First, the
increase in flow associated with systemic vaso-
dilatation will increase the diastolic filling rate
and, consequently, also the viscous component of
the LV compliance [31]. Second, profound
coronary vasodilatation may increase the LV wall
volume relative to LV chamber volume [32].
Third, an increase in RV end-diastolic dimensions
may decrease the LV distensibility by the
mechanism of ventricular interdependence [33].
All three factors would counterbalance the effects
of an acute reduction in afterload on the LV
pressure-volume relation by shifting it in the
opposite direction. The net result would be an
unchanged LVEDP (as observed), despite sub-
stantial changes in LV afterload.
Compared with the LV, the RV operated under
clearly different loading conditions. Indices of RV
preload (end-diastolic dimensions and pressure)
increased and indices of RV afterload (PAP, PVR)
remained unchanged. In contrast to the LV, the
increase in output was associated with an increase
in preload (fig. 2). It remains to be determined
whether this represents an upward shift along the
same ventricular function curve, or a right- and
downward shift to a different ventricular function
curve, indicating myocardial depression. Differ-
ences in RV and LV regional myocardial per-
formance are probably related to the different
effects of diltiazem on the afterload of the RV
(unchanged) and on that of the LV (reduced).
This could have potentially important clinical
implications for patients receiving diltiazem in the
presence of increased RV afterload.
In contrast to the preservation of global RV and
LV function during fentanyl anaesthesia noted in
this study, in the presence of volatile anaesthetics,
diltiazem has been shown to be a potent myo-
cardial depressant [10, 17, 18]. This might have
been the result of absence of afterload reduction,
underlying myocardial depression caused by in-
halation anaesthetics or impaired baroreceptor
reactivity. In the present study, the increase in
HR following the bolus injections of nitro-
glycerin indicated that baroreceptor function
was preserved, even during the high-dose infusion
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of diltiazem. It is, therefore, to be expected that
the net haemodynamic response to diltiazem will
depend on the kind of application (bolus v.
infusion), the state of wakefulness (awake v.
anaesthetized), and the baseline anaesthetic
(i.v. v. inhalation).
Diltiazem and cardiac rate and rhythm
We observed a dose-dependent increase in the
duration of the PR interval during the infusion of
diltiazem. This observation is in agreement with
other experimental and human studies: diltiazem
has a profound effect on sinus and atrioventricular
pacemakers, both nodes being slow calcium
channel dependent tissues [34].
Except for a 10% increase following the first
bolus injection, HR remained unaffected. In vitro,
diltiazem exhibits direct dose-dependent negative
chronotropic effects [27, 34]. In awake subjects,
however, HR tends to decrease minimally [3, 35],
and in conscious animals there may even be a
dose-dependent increase in HR [27, 36]. As the
increase in HR following the first bolus injection
of diltiazem indicates, the suppressant effect of
diltiazem on the sinoatrial node in vitro is
apparently modified in vivo by the reflex increase
in sympathetic tone which results from the
decrease in arterial pressure [34]. Moreover,
pancuronium was used in this study and might
antagonize the negative chronotropic effect of
diltiazem [37]. As suggested by the absence of any
increase in HR in response to the second bolus
injection, at high plasma concentrations direct
negative chronotropic effects may suppress the
reflex increase in HR.
Diltiazem caused progressive alterations in
electrophysiological variables. During both in-
fusions the PR intervals increased in a dose-
dependent manner and, during the high infusion
rate, three animals developed atrioventricular
block. This clearly reflects impaired atrio-
ventricular conduction. However, the develop-
ment of atrioventricular block might be limited by
the facilitating effect of pancuronium on atrio-
ventricular conduction [37]. Similar increases in
PR interval and similar arrhythmias at similar
plasma concentrations have been reported pre-
viously [6, 38, 39]. This suppressant effect on the
atrioventricular node is also seen clinically [34],
but it is less pronounced and, at times, occurs only
at considerably higher plasma concentrations
[35]. On the other hand, during isoflurane anaes-
thesia in dogs, PR intervals increased at consider-
ably lower plasma diltiazem concentrations [17].
Despite five-fold higher plasma concentrations
after the bolus injections (rather than during the
infusion) PR intervals did not increase following
either bolus injection. This might have been
because of a greater reflex increase in sympathetic
tone in response to the more pronounced decrease
in arterial pressure.
The durations of the QRS interval and QTC
remained unchanged throughout. This was to be
expected because, in contrast to the slow calcium
channel-dependent tissues of sinus and atrio-
ventricular nodes, the His-Purkinje system and
the ventricular muscle are fast channel-dependent
tissues in which the inward current is not
primarily carried by calcium ions. This is consis-
tent with the finding of an unchanged ventricular
muscle effective refractory period in anaesthetized
animals at plasma concentrations which signi-
ficantly depressed antrioventricular node function
[38].
Clinical implications
Diltiazem proved to be a potent coronary and
systemic vasodilator without adverse effects on
heart rate and global pump function. Con-
sequently, under similar clinical conditions (for
example, open heart surgery during neurolept-
anaesthesia), diltiazem might improve myocardial
oxygen balance by decreasing oxygen demand
and increasing oxygen supply. Our results
were obtained in animals with presumed normal
coronary arteries and myocardium, and the results
cannot be extrapolated directly to patients with
coronary artery disease. However, beneficial
effects of diltiazem have been demonstrated in
different types of experimental ischaemia [40—45].
These data indicate that diltiazem may be suitable
for the treatment of perioperative ischaemia.
Moreover, diltiazem has been shown to prevent
sympathetically-mediated constriction of normal
and diseased coronary arteries in man [46]. This
effect may be important in preventing coronary
vasoconstriction and myocardial ischaemia as a
result of sympathetic stimulation during the
perioperative period. However, some of the
beneficial effects of diltiazem may be lost during
the infusion of high doses as a result of the
development of clinically relevant myocardial
depression and abnormalities of conduction.
Therefore, bolus injections of diltiazem might
be preferable.
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